Recent Press Releases

Dauntless Pharmaceuticals and Aegis Therapeutics Announce Licensing Agreement

San Diego, Calif. July 21, 2015 – Dauntless Pharmaceuticals, Inc. (Dauntless), a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC (Aegis)...

Dauntless Pharmaceuticals Launches New Company Focused on Developing a Portfolio of Improved Therapeutics

SAN DIEGO, July 21, 2015 /PRNewswire/ -- Dauntless Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of specialty drugs, today announced the closing of a $12 million...

UCB announces Phase 3 clinical trial program for epratuzumab in Systemic Lupus Erythematosus did not meet primary endpoint

UCB remains committed to delivering value for patients living with lupus and other serious immunologic diseases BRUSSELS, Belgium I July 28, 2015 I UCB today announced that the two EMBODY™...

Alnylam Initiates Phase 1/2 Clinical Trial for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

– Company Expects to Present Initial Clinical Results in Early 2016 – July 27, 2015 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--()--Alnylam Pharmaceuticals,...

leon-nanodrugs GmbH Raises EUR 18.5 Million in Series A Financing

MUNICH, July 27, 2015 /PRNewswire/ -- TVM Capital Life Science leads international syndicate of investors - an additional EUR 3 million investment is expected later in 2015 leon nanodrugs GmbH...

Ra Pharmaceuticals Announces $58.5M Series B Financing

Published: July 23, 2015 9:00 a.m. ET -- Complement C5 Inhibitor Peptide Poised to Enter Clinical Evaluation for Paroxysmal Nocturnal Hemoglobinuria----Multi-target Collaboration with Merck...

Ra Pharmaceuticals Announces $58.5M Series B Financing

Published: July 23, 2015 9:00 a.m. ET -- Complement C5 Inhibitor Peptide Poised to Enter Clinical Evaluation for Paroxysmal Nocturnal Hemoglobinuria----Multi-target Collaboration with Merck...

New Method to Deliver Glucose to Cancer Cells Could Prove Key to Defeating Deadly Cancers

Results provide evidence that drugs used to treat diabetes could be used to reduce tumor growth in pancreatic and prostate cancers Newswise — UCLA scientists have for the first time identified...

Delcath Receives Orphan Drug Designation From FDA For Melphalan To Treat Cholangiocarcinoma

NEW YORK, July 20, 2015 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary...

Novo Nordisk Receives FDA Approval for FlexPro® PenMate® for People with Growth Hormone-Related Disorders

FlexPro® PenMate® designed for Norditropin® (somatropin [rDNA origin] injection) patients who dislike needles PLAINSBORO, N.J., July 16, 2015 /PRNewswire/ -- Novo Nordisk announced today...

pSivida Announces Positive Top Line Results From Investigator-Sponsored Phase II Study of Medidur™ for Uveitis

July 13, 2015 07:30 AM Eastern Daylight Time WATERTOWN, Mass.--()--pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products...

New technique for precise light-activated chemotherapy drugs

A new technique that uses light to activate chemotherapy drugs in specific cells shows promise as a way to improve the effectiveness of cancer therapies while preventing severe side effects,...

EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis

WALTHAM, Mass., Jul 10, 2015 (GLOBE NEWSWIRE via COMTEX) -- Eyegate Pharmaceuticals, Inc. (otcqb:EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that...

Biogen and AGTC Enter Collaboration to Develop Gene Therapies in Ophthalmology

Companies to advance a potentially transformative treatment approach for genetic diseases of the eye AGTC to receive $124M upfront, with potential future milestone payments and royalties AGTC to host...

Macrophage Therapeutics Reports Data Demonstrating a Manocept™ Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi's Sarcoma and Tumor Associated Macrophages

- Results demonstrated programmed cell death in KS tumor cells and anti-HIV activity - - Reinforces therapeutic potential of targeting activated macrophages via the CD206 receptor - July 02, 2015...

Pfizer Announces FDA Acceptance for Review of New Drug Application for A Once-Daily Formulation of XELJANZ® (tofacitinib citrate) Modified Release Tablets

July 02, 2015 04:30 PM Eastern Daylight Time NEW YORK--()--Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) accepted for review Pfizer's new...

ProLynx Awarded NSF Supplement to Develop Its Hydrogel Drug Delivery System to Treat Inner Ear Disorders

SAN FRANCISCO, June 29, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension, announced the receipt of a...

OptiNose Announces Positive Results of Phase III Trial for OPN-375

OPN-375, in Development for Chronic Rhinosinusitis with and without Nasal Polyps, Demonstrated Statistically Significant Benefits in Patients with Nasal Polyps June 24, 2015 08:30 AM Eastern Daylight...

A Gel That Can Make Drugs Last Longer, A*STAR Study

Researchers at the Institute of Bioengineering and Nanotechnology (IBN) of A*STAR have developed a drug-delivering hydrogel to treat chronic diseases such as hepatitis C, a liver disease that kills...

Cynapsus Therapeutics Enrolls First Patient in Pivotal Phase 3 Efficacy Study Evaluating Sublingual, Film Strip Delivery of Apomorphine to TurnParkinson's Disease Patients from the OFF to the ON State

CTH-300 Clinical Trial to Assess Effectiveness and Safety of APL-130277 Monday, June 29, 2015 TORONTO – (Marketwired) – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) (the...